2018 - Member of Academia Europaea
His Biochemistry study frequently draws connections between adjacent fields such as Gene isoform. In most of his Receptor studies, his work intersects topics such as Antagonist. As part of his studies on Antagonist, he frequently links adjacent subjects like Receptor. His work on Dihydropyridine expands to the thematically related Calcium. Dihydropyridine is closely attributed to Calcium in his work. In his research, Jörg Striessnig performs multidisciplinary study on Internal medicine and Endocrinology. In his works, he performs multidisciplinary study on Endocrinology and Internal medicine. His multidisciplinary approach integrates Gene and Peptide sequence in his work. His study brings together the fields of Biochemistry and Peptide sequence.
Within the field of Protein subunit and Mutation Jörg Striessnig studies Gene. Jörg Striessnig has begun a study into Receptor, looking into Ion channel and Antagonist. As part of his studies on Antagonist, Jörg Striessnig often connects relevant subjects like Receptor. His study in T-type calcium channel extends to Calcium with its themes. Much of his study explores Biochemistry relationship to Binding site. His Biochemistry research extends to the thematically linked field of Binding site. His Organic chemistry study frequently involves adjacent topics like Dihydropyridine. His study brings together the fields of Calcium and Dihydropyridine. His research ties Gating and Biophysics together.
Gene and splice are frequently intertwined in his study. Splice is closely attributed to Gene in his study. While working in this field, Jörg Striessnig studies both Pharmacology and Drug discovery. He performs integrative study on Drug discovery and Pharmacology. As part of his studies on Genetics, Jörg Striessnig often connects relevant areas like HEK 293 cells. His study ties his expertise on Genetics together with the subject of HEK 293 cells. Neuroscience is closely attributed to Brugada syndrome in his study. His research links Neuroscience with Brugada syndrome. His Key (lock) study frequently links to adjacent areas such as Computer security.
Jörg Striessnig combines Computational biology and Bioinformatics in his studies. He undertakes interdisciplinary study in the fields of Bioinformatics and Computational biology through his works. He integrates many fields in his works, including Pharmacology and Drug discovery. Jörg Striessnig undertakes multidisciplinary investigations into Drug discovery and Pharmacology in his work. He performs multidisciplinary study in Clinical pharmacology and Internal medicine in his work. Jörg Striessnig brings together Internal medicine and Clinical pharmacology to produce work in his papers. His Computer security study frequently involves adjacent topics like Key (lock). Key (lock) is often connected to Computer security in his work. In his research, Jörg Striessnig performs multidisciplinary study on G protein-coupled receptor and Receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Purification, molecular cloning, and expression of the mammalian sigma1-binding site
Markus Hanner;Fabian F. Moebius;Astrid Flandorfer;Hans-Gunther Knaus.
Proceedings of the National Academy of Sciences of the United States of America (1996)
Congenital Deafness and Sinoatrial Node Dysfunction in Mice Lacking Class D L-Type Ca2+ Channels
Josef Platzer;Jutta Engel;Anneliese Schrott-Fischer;Kurt Stephan.
Neurobiology of migraine.
Daniela Pietrobon;Jörg Striessnig.
Nature Reviews Neuroscience (2003)
The Concise Guide to PHARMACOLOGY 2017/18: Overview
Stephen P. H. Alexander;Eamonn Kelly;Neil V. Marrion;John A. Peters.
British Journal of Pharmacology (2017)
α1D (Cav1.3) Subunits Can Form L-type Ca2+ Channels Activating at Negative Voltages
Alexandra Koschak;Daniel Reimer;Irene G. Huber;Manfred Grabner.
Journal of Biological Chemistry (2001)
Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity.
Matteo E. Mangoni;Brigitte Couette;Emmanuel Bourinet;Josef Platzer.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Receptor sites for Ca2+ channel antagonists
William A. Catterall;Jörg Striessnig.
Trends in Pharmacological Sciences (1992)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets.
Stephen P.H. Alexander;Eamonn Kelly;Alistair Mathie;John A. Peters.
British Journal of Pharmacology (2019)
Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouse.
Claudia Seisenberger;Verena Specht;Andrea Welling;Josef Platzer.
Journal of Biological Chemistry (2000)
Loss of Ca v 1.3 ( CACNA1D ) function in a human channelopathy with bradycardia and congenital deafness
Shahid M Baig;Alexandra Koschak;Andreas Lieb;Mathias Gebhart.
Nature Neuroscience (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: